Viking Therapeutics (VKTX) Stock Looks Above Fair Value Today

Viking Therapeutics has delivered a very large 5 year return for shareholders, yet at around US$33.86 per share today the stock still screens as expensive on Simply Wall St's valuation checks. Recent share price weakness adds another layer, with the broader valuation score not pointing to an obvious bargain despite the long term gains.

• Viking Therapeutics has returned about 467% over 5 years, which puts extra focus on whether the current price already reflects a lot of optimism.
• Excitement around new diabetes and metabolic treatments can support high expectations for Viking Therapeutics, while execution risk and future funding needs may weigh on how much investors are prepared to pay.
• The company passes 0 of 6 valuation checks on Simply Wall St, which means the stock leans expensive rather than reading as a clear bargain on the broader metrics 0/6.

The issue now is whether Viking Therapeutics' strong long term return history justifies paying what the current valuation metrics are implying.

Find out why Viking Therapeutics' 2.9% return over the last year is lagging behind its peers.

Has Viking Therapeutics Run Too Far on Book Value?

P/B can be a useful cross check for Viking Therapeutics because the company is still loss making and does not have a meaningful P/E yet.

On this measure, Viking Therapeutics trades at about 7.8x book value. That is above both the biotech industry average of roughly 2.4x and the peer group average of about 6.3x. The gap indicates investors are paying a premium to the sector for the company’s asset base, even before considering any future revenue traction.

Despite the recent interest in new diabetes and metabolic therapies across the sector, this premium leaves the stock screening as expensive on a simple balance sheet yardstick. The valuation model also heavily weights the current losses, which underscores that the shares are priced above what many biotech companies command on book value alone.

On the P/B multiple, Viking Therapeutics currently screens as more expensive relative to both its industry and closer peers.

See what the numbers say about this price — find out in our valuation breakdown.

The Viking Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Viking Therapeutics pick up where the valuation checks leave off and focus on what would need to happen with Viking Therapeutics' growth, margins and future earnings for the stock to be worth materially more or less than today’s price. Instead of a single output from a ratio or model, Narratives describe the future that number depends on so you can follow how events line up with it over time on the Community page.

One of the top community narratives on Viking Therapeutics: 73% undervalued

"The large, global demand for obesity treatments is aligning with VK2735’s late-stage development in two formulations, which positions Viking Therapeutics to address a wide range of patient preferences…"

Read one of the top narratives on Viking Therapeutics

Do you think there's more to the story for Viking Therapeutics? Head over to our Community to see what others are saying!

The Bottom Line

Viking Therapeutics now screens as overvalued on market multiples, with a price that sits well above both sector and close peer benchmarks on P/B. That does not rule out further upside. However, it does mean a lot of success with its diabetes and metabolic pipeline already sits in the valuation. The real divide between bulls and bears is whether future trial results and eventual commercial execution will be strong enough to keep investors comfortable paying this premium multiple.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com